This ANDA is approved for its use in combination with Prednisone.
Abiraterone Acetate Tablets, USP, 250 mg and 500 mg, are the generic version of Zytiga for treatment of metastatic prostate cancer.
Amneal immediately initiated commercialization activities upon the approval of the additional 500 mg strength.
According to IQVIA, a leading healthcare data and analytics provider, US annual sales for Abiraterone Tablets, USP, 500 mg, for the 12 months ended November 2020 were approximately USD 413m.
Important Safety Information includes the possibility of mineralocorticoid excess; adrenocortical insufficiency; hepatotoxicity; increased fractures and mortality in combination with radium Ra 223 dichloride; embryo-fetal toxicity; and hypoglycemia.
Reported adverse reactions include hypertension, hypokalemia, arthralgia and edema. Reported laboratory abnormalities include anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hyperglycemia, hypercholesterolemia and hypokalemia.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products.
The company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling